The acceptance of innovative hormonal therapy for advanced prostate cancer is racialized.

Published Date: 03 Jan 2024

The use of novel hormonal therapy (NHT) agents for Medicare beneficiaries with advanced prostate cancer (PCa) differs based on race, per a study published online Dec. 1 in JAMA Network Accessible.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

2.

Elder Abuse: Red Flags to Look Out For While Receiving Care.

3.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.

4.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

5.

Scientists pioneer noninvasive 3D imaging to enhance skin cancer management


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot